Cost-effective recombinant protein production


Cost-effective recombinant protein production


engenes_Logo_final1

Products & Services | enGenes Biotech GmbH

Overview:

enGenes Biotech has developed customized solutions for the cost-effective production of recombinant proteins in microbial expression systems.

The solutions are leveraged from enGenes’ world-class experience in cutting-edge genetic engineering, combined with a broad expertise in bioprocess engineering, to produce best-in-class protein expression systems.

The company’s unique enGenes-X-press™ Escherichia coli (E.coli) proprietary technology forms a production platform that achieves outstanding yields of soluble and active recombinant protein by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.

Expression services

Internationally recognized scientists founded enGenes Biotech to operate in the field of microbial-based protein expression, based on their extensive track-record of scientific publications, patents and a strong understanding for the requirements of the biotech industry built up over years of international cooperation.

Based on this extensive knowledge and method portfolio, enGenes can deliver improved host cell lines, plasmid expression vectors and optimized production processes to maximize bioprocess efficacy and to enable most cost-effective manufacturing.

Customized project plans also responds to individual documentation requirements to support easy technology transfer to clients’ own facilities and quality management systems.

These services are designed to adequately cover all specific demands along the line from gene to protein, with options that include:

  • Cloning / Vector optimization
  • Generation of expression strain and host cell engineering
  • Bioprocess development and bioprocess optimization (USP & DSP)
  • Establishing of purification protocol and final purification
  • Non-GMP mg- to g-scale production of purified proteins
  • Feasibility studies for the proprietary enGenes-X-press™ technology

Technologies;

enGenes-X-press™ constitutes the next-generation E. coli expression platform that allows for scalable production of difficult-to-express or even “toxic” recombinant proteins at a fraction of their current cost. Patents are pending on X-press technology as a growth-decoupled microbial protein production system.

In addition, enGenes is also developing IP in the following research fields:

  • Improved plasmid vector expression systems
  • Antibiotic resistance-free plasmid selection for the production of recombinant proteins

Applications

enGenes expression products and services are highly relevant for companies with interest in developing cost-effective manufacturing processes for recombinant proteins. The world-leading X-press technology for growth-decoupled protein production allows enGenes to develop economic, scalable and efficient production processes within short time frames to enhance the commercial success of unique products.

Prokaryotic protein expression in E.coli

enGenes offers a modular system of customer services for gene expression and protein production in Escherichia coli and other prokaryotes (e.g. Bacillus subtilis). The prokaryotic expression service, focused on the expression of difficult-to-express proteins, is divided into a customer menu of steps that include:

  • Design & engineering
  • Feasibility studies for research and proof-of-concept studies (POC)
  • Bioprocess development and optimization
  • Non-GMP pilot production (mg- to g-scale)
  • Process transfer to CMO

These steps can be performed either individually or in combination, allowing clients to tailor the process to individual requirements.

Resources

Click on Recombinant protein expression and production for more information.
Click on enGenes Biotech GmbH to contact the company directly.

DSC_3747


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Comments are closed.